Scarica l'app Stockscreener
44.38
0.23%
0.10
Pre-mercato:
45.08
0.70
+1.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$44.28
Aprire:
$44.13
Volume 24 ore:
2.07M
Relative Volume:
0.77
Capitalizzazione di mercato:
$11.53B
Reddito:
$2.32B
Utile/perdita netta:
$782.57M
Rapporto P/E:
15.94
EPS:
2.7838
Flusso di cassa netto:
$875.84M
1 W Prestazione:
-2.27%
1M Prestazione:
+8.06%
6M Prestazione:
+13.19%
1 anno Prestazione:
+22.77%
Intervallo 1D:
$43.97
$44.69
Intervallo di 1 settimana:
$43.75
$46.10
Portata 52W:
$33.76
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.38 | 11.50B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Here's why Exelixis (EXEL) is a strong momentum stock - MSN
Do Options Traders Know Something About Exelixis Stock We Don't? - MSN
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT - MSN
Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib (NASDAQ:EXEL) - Seeking Alpha
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
EXEL | Exelixis Inc Executive Compensation - Quiver Quantitative
EXELIXIS, INC. ($EXEL) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay and equity plan on ballot at Exelixis (NASDAQ: EXEL) 2026 meeting - Stock Titan
Exelixis: Stable Demand And High Margins With Undervalued Shares (NASDAQ:EXEL) - Seeking Alpha
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators - Markets Mojo
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Working capital per share of Exelixis, Inc. – BX:EX9 - TradingView — Track All Markets
Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference - Yahoo
EXELAnnual Report (10-k) - ADVFN
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - ADVFN
Neuroendocrine Tumor Treatment Market size to cross $5.12 - openPR.com
How (EXEL) Movements Inform Risk Allocation Models - Stock Traders Daily
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Do Upgraded 2026 Earnings Forecasts Alter the Growth Narrative for Exelixis (EXEL)? - Sahm
Stock Report: Can Exelixis Inc sustain its profitability2026 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Nisa Investment Advisors LLC Has $6.16 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Tema Etfs LLC Grows Position in Exelixis, Inc. $EXEL - MarketBeat
Allspring Global Investments Holdings LLC Has $60.31 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Moving Averages: Is Exelixis Inc a play on infrastructure spendingGlobal Markets & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Eastern Progress
Exelixis: A Strong Contender in the Cancer Drug Market - The Globe and Mail
Kidney Cancer Drugs Market to Grow by $2 Billion During - GlobeNewswire
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry - Yahoo Finance
Exelixis Inc. (NASDAQ:EXEL) Presents a Compelling Value Investment Case - ChartMill
Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Trading Systems Reacting to (EXEL) Volatility - Stock Traders Daily
Exelixis, Inc. $EXEL Stake Lowered by Assenagon Asset Management S.A. - MarketBeat
RBC Capital lowers Exelixis (EXEL) price target to $43 - MSN
MIC:EXEL-RM OCF Yield %: 8.20 — 52% Above Median - GuruFocus
Exelixis, Inc. $EXEL Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 - Insider Monkey
15 Set-It-and-Forget-It Stocks to Buy in 2026 - Insider Monkey
Exelixis (MIC:EXEL-RM) NonCurrent Deferred Revenue : ₽0.00 Mil (As of Dec. 2025) - gurufocus.com
EXEL Technical Analysis | Trend, Signals & Chart Patterns | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
EXEL Financials: Income Statement, Balance Sheet & Cash Flow | Exelixis Inc - Stock Titan
Vanguard disaggregates holdings; Exelixis (NASDAQ: EXEL) shows 0 shares - Stock Titan
Exelixis (NASDAQ:EXEL) Raised to Strong-Buy at Truist Financial - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by Nordea Investment Management AB - MarketBeat
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
EXEL Stock Price, Quote & Chart | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Quarterly Trades: Will Exelixis Inc outperform its industry peersMarket Volume Report & Capital Protection Trade Alerts - baoquankhu1.vn
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):